Scott Klug: “I want to go back, because I do not think we can stress this often enough, to what is at stake in FDA reform, period.…”

“I want to go back, because I do not think we can stress this often enough, to what is at stake in FDA reform, period. Because you managed, Mr. Greenwood, at the end of your conversation with Mr. Barton, I think, to put a very human face on what happens with FDA reform. I can remember standing about 6 weeks ago in a press conference in Madison with the family of a young boy, Cody Young, who lives in Baraboo about an hour from Madison, the place where the Ringling Brothers Circus was founded. And he has a severe case of epilepsy. And the tragedy of this story, as you will hear over and over tonight, is that the original medication developed for Cody Young's severe case of epilepsy was first conceived at a United States research facility. It was tested in the United States, and it now sits essentially at the FDA's desk, ready to be approved, while the drug is already available in Switzerland. And here is Cody Young's family saying, I do not get it. Developed in the United States, first tested in the United States, ready to be marketed in the United States; and the FDA has it tangled up in bureaucratic redtape while it is available to citizens in Europe.”